Utilization and efficacy of second-line targeted therapy in
metastatic renal cell carcinoma: data from a national registry

J 2017

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

LAKOMÝ, Radek, Alexandr POPRACH, Zbyněk BORTLÍČEK, B. MELICHAR, Renata CHLOUPKOVÁ et. al.

Základní údaje

Originální název

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Autoři

LAKOMÝ, Radek (203 Česká republika, garant, domácí), Alexandr POPRACH (203 Česká republika, domácí), Zbyněk BORTLÍČEK (203 Česká republika, domácí), B. MELICHAR (203 Česká republika), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Rostislav VYZULA (203 Česká republika, domácí), M. ZEMANOVA (203 Česká republika), K. KOPECKOVA (203 Česká republika), Marek SVOBODA (203 Česká republika, domácí), Ondřej SLABÝ (203 Česká republika, domácí), Igor KISS (203 Česká republika, domácí), H. STUDENTOVA (203 Česká republika), Jaroslav JURÁČEK (203 Česká republika, domácí), O. FIALA (203 Česká republika), J. KOPECKY (203 Česká republika), J. FINEK (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí), Karel HEJDUK (203 Česká republika, domácí) a T. BUCHLER (203 Česká republika)

Vydání

BMC Cancer, London, BioMed Central, 2017, 1471-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.288

Kód RIV

RIV/00216224:14110/17:00095691

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/s12885-017-3901-5

UT WoS

000418719700004

Klíčová slova anglicky

Renal cell carcinoma; Therapy; Sunitinib; Sorafenib; Everolimus; Pazopanib

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 4. 2021 13:40, Mgr. Tereza Miškechová

Anotace

V originále

Background: It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective, registry-based study using data from the national registry of targeted therapies for mRCC. The RENIS registry contains data on 3049 patients who started the therapy with at least one targeted agent before 31 December, 2014. Of these patients, 1029 had a record of at least two different targeted therapies and sufficient data for analysis. Survival analysis was carried out using the Kaplan-Meier method. Statistical significance of differences in survival between subgroups was assessed using the log-rank test. Results: The median overall survival from the start of second-line treatment was 17.0 months (95% confidence interval [CI] 14.5-19.5 months), 17.1 months (95% CI 14.5-19.8), and 15.4 months (95% CI 11.0-19.7) for second-line everolimus, sorafenib, and sunitinib, respectively. Patients receiving second-line everolimus were older at the start of second-line treatment, more likely to have metachronous disease, and less likely to be previously treated with cytokines or to continue to third-line treatment than patients treated with second-line sunitinib or sorafenib. Progression-free survival (PFS) correlated with PFS on first-line treatment only for everolimus. Conclusions: In this retrospective study, no significant differences in survival were observed between the cohorts treated with different second-line agents including everolimus, sorafenib, and sunitinib.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NT13547, projekt VaV

Název: Studium mikroRNA a genů asociovaných s procesem epiteliálně-mezenchymální tranzice jako potenciálních markerů pro predikci rizika a časný záchyt metastazování u pacientů s renálním karcinomem

NV15-34678A, projekt VaV

Název: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

90004, velká výzkumná infrastruktura

Název: BBMRI-CZ

Citovat

LAKOMÝ, Radek, Alexandr POPRACH, Zbyněk BORTLÍČEK, B. MELICHAR, Renata CHLOUPKOVÁ, Rostislav VYZULA, M. ZEMANOVA, K. KOPECKOVA, Marek SVOBODA, Ondřej SLABÝ, Igor KISS, H. STUDENTOVA, Jaroslav JURÁČEK, O. FIALA, J. KOPECKY, J. FINEK, Ladislav DUŠEK, Karel HEJDUK a T. BUCHLER. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer. London: BioMed Central, 2017, roč. 17, č. 880, s. 1-8. ISSN 1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-017-3901-5.

@article{1402032,
   author = {Lakomý, Radek and Poprach, Alexandr and Bortlíček, Zbyněk and Melichar, B. and Chloupková, Renata and Vyzula, Rostislav and Zemanova, M. and Kopeckova, K. and Svoboda, Marek and Slabý, Ondřej and Kiss, Igor and Studentova, H. and Juráček, Jaroslav and Fiala, O. and Kopecky, J. and Finek, J. and Dušek, Ladislav and Hejduk, Karel and Buchler, T.},
   article_location = {London},
   article_number = {880},
   doi = {http://dx.doi.org/10.1186/s12885-017-3901-5},
   keywords = {Renal cell carcinoma; Therapy; Sunitinib; Sorafenib; Everolimus; Pazopanib},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry},
   url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3901-5},
   volume = {17},
   year = {2017}
}

TY  - JOUR
ID  - 1402032
AU  - Lakomý, Radek - Poprach, Alexandr - Bortlíček, Zbyněk - Melichar, B. - Chloupková, Renata - Vyzula, Rostislav - Zemanova, M. - Kopeckova, K. - Svoboda, Marek - Slabý, Ondřej - Kiss, Igor - Studentova, H. - Juráček, Jaroslav - Fiala, O. - Kopecky, J. - Finek, J. - Dušek, Ladislav - Hejduk, Karel - Buchler, T.
PY  - 2017
TI  - Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
JF  - BMC Cancer
VL  - 17
IS  - 880
SP  - 1-8
EP  - 1-8
PB  - BioMed Central
SN  - 14712407
KW  - Renal cell carcinoma
KW  - Therapy
KW  - Sunitinib
KW  - Sorafenib
KW  - Everolimus
KW  - Pazopanib
UR  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3901-5
N2  - Background: It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate the outcomes of patients treated with second-line targeted therapy for metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective, registry-based study using data from the national registry of targeted therapies for mRCC. The RENIS registry contains data on 3049 patients who started the therapy with at least one targeted agent before 31 December, 2014. Of these patients, 1029 had a record of at least two different targeted therapies and sufficient data for analysis. Survival analysis was carried out using the Kaplan-Meier method. Statistical significance of differences in survival between subgroups was assessed using the log-rank test. Results: The median overall survival from the start of second-line treatment was 17.0 months (95% confidence interval [CI] 14.5-19.5 months), 17.1 months (95% CI 14.5-19.8), and 15.4 months (95% CI 11.0-19.7) for second-line everolimus, sorafenib, and sunitinib, respectively. Patients receiving second-line everolimus were older at the start of second-line treatment, more likely to have metachronous disease, and less likely to be previously treated with cytokines or to continue to third-line treatment than patients treated with second-line sunitinib or sorafenib. Progression-free survival (PFS) correlated with PFS on first-line treatment only for everolimus. Conclusions: In this retrospective study, no significant differences in survival were observed between the cohorts treated with different second-line agents including everolimus, sorafenib, and sunitinib.
ER  -

LAKOMÝ, Radek, Alexandr POPRACH, Zbyněk BORTLÍČEK, B. MELICHAR, Renata CHLOUPKOVÁ, Rostislav VYZULA, M. ZEMANOVA, K. KOPECKOVA, Marek SVOBODA, Ondřej SLABÝ, Igor KISS, H. STUDENTOVA, Jaroslav JURÁČEK, O. FIALA, J. KOPECKY, J. FINEK, Ladislav DUŠEK, Karel HEJDUK a T. BUCHLER. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. \textit{BMC Cancer}. London: BioMed Central, 2017, roč.~17, č.~880, s.~1-8. ISSN~1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-017-3901-5.

Podrobný výpis o publikaci